Stockreport

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

Biodesix, Inc.  (BDSX) 
PDF Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue G [Read more]